{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:40:11Z","timestamp":1793032811510,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":115,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2019IP0599"],"award-info":[{"award-number":["2019IP0599"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ImmuneOncia Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01571-2","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:24:05Z","timestamp":1783059845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study"],"prefix":"10.1038","volume":"10","author":[{"given":"Yeong Hak","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Won","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Won","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hye","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho June","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee Don","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yeob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Ryun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","journal-title":"Science"},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234\u2013247 (2022).","journal-title":"Lancet Oncol."},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima, T. et al. Randomized Phase III KEYNOTE-181 study of Pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138\u20134148 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1571_CR10","doi-asserted-by":"crossref","unstructured":"Park, J. E. et al. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J. Immunother. Cancer 8, e000873 (2020).","DOI":"10.1136\/jitc-2020-000873"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s10637-021-01078-6","volume":"39","author":"B Keam","year":"2021","unstructured":"Keam, B. et al. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investig. N. Drugs 39, 1624\u20131632 (2021).","journal-title":"Investig. N. Drugs"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hon.3164_433","volume":"41","author":"WS Kim","year":"2023","unstructured":"Kim, W. S. et al. Phase 2 study to investigate the efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK\/T cell lymphoma, nasal type: DISTINKT Study. Hematol. Oncol. 41, 578\u2013579 (2023).","journal-title":"Hematol. Oncol."},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2025-5426","volume":"146","author":"WS Kim","year":"2025","unstructured":"Kim, W. S. et al. Artificial intelligence (AI)\u2013based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK\/T cell lymphoma (R\/R ENKTL): Insights from the Phase II trial (DISTINKT). Blood 146, 5426\u20135426 (2025).","journal-title":"Blood"},{"key":"1571_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep31355","volume":"6","author":"MA Cavadas","year":"2016","unstructured":"Cavadas, M. A. et al. REST is a hypoxia-responsive transcriptional repressor. Sci. Rep. 6, 31355 (2016).","journal-title":"Sci. Rep."},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"a014415","DOI":"10.1101\/cshperspect.a014415","volume":"3","author":"M Huang","year":"2013","unstructured":"Huang, M. & Weiss, W. A. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 3, a014415 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1571_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.14740\/wjon1595","volume":"14","author":"Y Song","year":"2023","unstructured":"Song, Y. & Ma, R. Comprehensive analysis reveals the potential roles of transcription factor Dp-1 in lung adenocarcinoma. World J. Oncol. 14, 205\u2013223 (2023).","journal-title":"World J. Oncol."},{"key":"1571_CR17","doi-asserted-by":"crossref","unstructured":"Sobolev, V. V. et al. Role of the transcription factor FOSL1 in organ development and tumorigenesis. Int. J. Mol. Sci. 23, 1521 (2022).","DOI":"10.3390\/ijms23031521"},{"key":"1571_CR18","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/onc.2017.151","volume":"36","author":"AR Lourenco","year":"2017","unstructured":"Lourenco, A. R. & Coffer, P. J. A tumor suppressor role for C\/EBPalpha in solid tumors: more than fat and blood. Oncogene 36, 5221\u20135230 (2017).","journal-title":"Oncogene"},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.7150\/ijbs.24329","volume":"14","author":"X Cai","year":"2018","unstructured":"Cai, X., Yao, Z., Li, L. & Huang, J. Role of DKK4 in tumorigenesis and tumor progression. Int. J. Biol. Sci. 14, 616\u2013621 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"1571_CR20","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.7150\/jca.110597","volume":"16","author":"Y Hu","year":"2025","unstructured":"Hu, Y. et al. DUSP9 is up-regulated and promotes tumor progression in head and neck squamous cell carcinoma. J. Cancer 16, 3403\u20133414 (2025).","journal-title":"J. Cancer"},{"key":"1571_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13000-018-0763-3","volume":"13","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Zhu, J., Huang, Y., Li, W. & Cheng, H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K\/AKT\/mTOR signaling pathway. Diagn. Pathol. 13, 85 (2018).","journal-title":"Diagn. Pathol."},{"key":"1571_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40291-024-00712-2","volume":"28","author":"MA Rosochowicz","year":"2024","unstructured":"Rosochowicz, M. A., Kulcenty, K. & Suchorska, W. M. Exploring the role of HtrA family genes in cancer: a systematic review. Mol. Diagn. Ther. 28, 347\u2013377 (2024).","journal-title":"Mol. Diagn. Ther."},{"key":"1571_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12253-018-0488-3","volume":"25","author":"A Popiel","year":"2019","unstructured":"Popiel, A., Kobierzycki, C. & Dziegiel, P. The role of testin in human cancers. Pathol. Oncol. Res. 25, 1279\u20131284 (2019).","journal-title":"Pathol. Oncol. Res."},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1038\/s41388-019-0759-9","volume":"38","author":"S Dang","year":"2019","unstructured":"Dang, S. et al. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene 38, 4804\u20134819 (2019).","journal-title":"Oncogene"},{"key":"1571_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133604","volume":"277","author":"C Li","year":"2024","unstructured":"Li, C. et al. A review of CDKL: an underestimated protein kinase family. Int. J. Biol. Macromol. 277, 133604 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13046-024-03203-8","volume":"43","author":"J Guo","year":"2024","unstructured":"Guo, J. et al. Hepatocyte-derived Igkappa promotes HCC progression by stabilizing electron transfer flavoprotein subunit alpha to facilitate fatty acid beta-oxidation. J. Exp. Clin. Cancer Res. 43, 280 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.18632\/aging.101563","volume":"10","author":"T Lin","year":"2018","unstructured":"Lin, T. et al. A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients\u2019 prognosis. Aging 10, 2480\u20132497 (2018).","journal-title":"Aging"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.7150\/ijbs.7224","volume":"9","author":"K Balamurugan","year":"2013","unstructured":"Balamurugan, K. & Sterneck, E. The many faces of C\/EBPdelta and their relevance for inflammation and cancer. Int. J. Biol. Sci. 9, 917\u2013933 (2013).","journal-title":"Int. J. Biol. Sci."},{"key":"1571_CR29","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1073\/pnas.1802279115","volume":"115","author":"XY Qin","year":"2018","unstructured":"Qin, X. Y. et al. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc. Natl. Acad. Sci. USA. 115, 4969\u20134974 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1571_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ijc.34893","volume":"155","author":"XY Qin","year":"2024","unstructured":"Qin, X. Y. et al. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. Int. J. Cancer 155, 582\u2013594 (2024).","journal-title":"Int. J. Cancer"},{"key":"1571_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16541-4","volume":"12","author":"L Qi","year":"2022","unstructured":"Qi, L., Ren, Z. & Li, W. E2F4 transcription factor is a prognostic biomarker related to immune infiltration of head and neck squamous cell carcinoma. Sci. Rep. 12, 12132 (2022).","journal-title":"Sci. Rep."},{"key":"1571_CR32","doi-asserted-by":"crossref","unstructured":"Lalle, G. et al. NF-kappaB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer. J. Exp. Med. 221, e20231348 (2024).","DOI":"10.1084\/jem.20231348"},{"key":"1571_CR33","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.7150\/ijbs.99590","volume":"20","author":"S Baral","year":"2024","unstructured":"Baral, S. et al. Transcription factor E2F4 promote proliferation, migration, and invasion of gastric cancer cells by transcriptionally activating DSCC1. Int. J. Biol. Sci. 20, 4978\u20134998 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"1571_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00794-w","volume":"27","author":"L Guo","year":"2022","unstructured":"Guo, L. & Liu, D. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma. Eur. J. Med. Res. 27, 164 (2022).","journal-title":"Eur. J. Med. Res."},{"key":"1571_CR35","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1097\/CM9.0000000000000296","volume":"132","author":"DB Chen","year":"2019","unstructured":"Chen, D. B. et al. Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase\/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis. Chin. Med. J. 132, 1572\u20131581 (2019).","journal-title":"Chin. Med. J."},{"key":"1571_CR36","doi-asserted-by":"crossref","unstructured":"Perevalova, A. M., Gulyaeva, L. F. & Pustylnyak, V. O. Roles of interferon regulatory factor 1 in tumor progression and regression: two sides of a coin. Int. J. Mol. Sci. 25, 2153 (2024).","DOI":"10.3390\/ijms25042153"},{"key":"1571_CR37","doi-asserted-by":"publisher","first-page":"104515","DOI":"10.1016\/j.ebiom.2023.104515","volume":"90","author":"G Zhang","year":"2023","unstructured":"Zhang, G. et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine 90, 104515 (2023).","journal-title":"EBioMedicine"},{"key":"1571_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat. Commun. 15, 9097 (2024).","journal-title":"Nat. Commun."},{"key":"1571_CR39","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","volume":"42","author":"SN Geels","year":"2024","unstructured":"Geels, S. N. et al. Interruption of the intratumor CD8+T cell: Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell 42, 1051\u20131066.e1057 (2024).","journal-title":"Cancer Cell"},{"key":"1571_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s42255-022-00585-x","volume":"4","author":"Z Hu","year":"2022","unstructured":"Hu, Z. et al. The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nat. Metab. 4, 759\u2013774 (2022).","journal-title":"Nat. Metab."},{"key":"1571_CR41","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1126\/science.1074900","volume":"297","author":"KB Nguyen","year":"2002","unstructured":"Nguyen, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297, 2063\u20132066 (2002).","journal-title":"Science"},{"key":"1571_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108891","volume":"34","author":"R Song","year":"2021","unstructured":"Song, R. et al. IRF1 governs the differential interferon-stimulated gene responses in human monocytes and macrophages by regulating chromatin accessibility. Cell Rep. 34, 108891 (2021).","journal-title":"Cell Rep."},{"key":"1571_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723\u2013750 (2018).","journal-title":"Hepatology"},{"key":"1571_CR44","unstructured":"Amin, M. B. et al. AJCC Cancer Staging Manual 8th edn. (Springer, 2017)."},{"key":"1571_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1571_CR46","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur. J. Cancer 35, 1773\u20131782 (1999).","journal-title":"Eur. J. Cancer"},{"key":"1571_CR47","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker, K. et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98, 1521\u20131530 (2003).","journal-title":"Cancer"},{"key":"1571_CR48","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.21.02010","volume":"40","author":"S Park","year":"2022","unstructured":"Park, S. et al. Artificial Intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer. J. Clin. Oncol. 40, 1916\u20131928 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1571_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104097","volume":"10","author":"C Park","year":"2025","unstructured":"Park, C. et al. Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications. ESMO Open 10, 104097 (2025).","journal-title":"ESMO Open"},{"key":"1571_CR50","doi-asserted-by":"crossref","unstructured":"Hwang, J. E. et al. Tumor immune microenvironment biomarkers for recurrence prediction in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. Cancers 16, 3363 (2024).","DOI":"10.3390\/cancers16193353"},{"key":"1571_CR51","doi-asserted-by":"publisher","first-page":"e008339","DOI":"10.1136\/jitc-2023-008339","volume":"12","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. J. Immunother. Cancer 12, e008339 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1571_CR52","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1158\/1078-0432.CCR-24-1265","volume":"30","author":"YH Bang","year":"2024","unstructured":"Bang, Y. H. et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer. Clin. Cancer Res. 30, 4635\u20134643 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1571_CR53","doi-asserted-by":"crossref","unstructured":"Bang, Y. H. et al. Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. J. Immunother. Cancer 13, e012374 (2025).","DOI":"10.1136\/jitc-2025-012374"},{"key":"1571_CR54","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1002\/cam4.3874","volume":"10","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Cancer Med. 10, 3197\u20133204 (2021).","journal-title":"Cancer Med."},{"key":"1571_CR55","doi-asserted-by":"publisher","first-page":"153678","DOI":"10.1016\/j.prp.2021.153678","volume":"228","author":"JS Jeong","year":"2021","unstructured":"Jeong, J. S., Cho, K. J., Kim, D., Lee, Y. S. & Song, J. S. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma. Pathol. Res. Pract. 228, 153678 (2021).","journal-title":"Pathol. Res. Pract."},{"key":"1571_CR56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"1571_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290\u2013295 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1571_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1571_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1571_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1571_CR61","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1093\/bioinformatics\/btz247","volume":"35","author":"K Vitting-Seerup","year":"2019","unstructured":"Vitting-Seerup, K. & Sandelin, A. IsoformSwitchAnalyzeR: analysis of changes in genome-wide patterns of alternative splicing and its functional consequences. Bioinformatics 35, 4469\u20134471 (2019).","journal-title":"Bioinformatics"},{"key":"1571_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01571-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:04:52Z","timestamp":1793030692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01571-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01571-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.P. has received institutional research funding from ImmuneOncia Therapeutics Inc., Incyte, and ONO Pharmaceutical; has served in a consultant\/advisory role for BeOne; and has received honoraria from Bristol Myers Squibb and Pfizer. The other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"404"}}